Another classic set up that was been constantly rewarding investors long the risk reversal trade. Sector was been showing strength as you go down the cap scale.
high and tight holds probably
If you haven`t bought ARDS before it went up 6X:
Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week,
I would consider purchasing the 4usd strike price Calls with
an expiration date of 2024-1-19,
for a premium of approximately $0.45.
If these options prove to be profitable prior to the earnings release,...
Biotechnology company Ardelyx Inc. has received FDA approval for its drug Xphozah. This medication is intended for treating kidney diseases and is typically recommended for patients with elevated kidney phosphorus levels. Xphozah could be a valuable addition to hemodialysis therapy since it is compatible with other drugs used for treating these conditions.
Let's...
Buy idea on ARDX as you see on the chart after the breakout with force the vwap indicator and the resistance line by a big green candle with a large green volume. In other hand, we will have a reversal trend if we have the breakout with force the support line by a big red candle with a large red volume. Thanks!
ARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally.
On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $5.00
This would be a 581% gain from the current level.
Looking...
Breakout above 2.2? and possible gap fill toward upside.
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:4, with the majority favoring treatment with the drug as monotherapy.
FDA decision soon. Risk is traditional sell the news event.
NASDAQ:ARDX
If it passes the bearish line it's time for a short position, and if it passes the bullish line it's time for the Long position, the price targets are on the chart.
Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year.
Since ARDX’s Market Cap is only...
Ardelyx shares are trading higher after Ladenburg Thalmann upgraded the stock from Neutral to Buy and announced a $6 price target. Also, Citigroup maintained a Buy rating and raised its price target from $7 to $13.
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and...
Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year.
Since ARDX’s Market Cap is...
Following the negative news that sent this stock into an 82% tailspin there is no viable buy signal aside from a simple long-term play.
Trend is continuing downward slowly. Has yet to find a solid support zone.
By way of Analyst Consensus, upside is above 100% but may take 12-months to materialize.
By way of previous share price average, upside is close to...
The FDA is unlikely to approve Ardelyx`s drug for dialysis patients.
Ardelyx received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought.
The most likely target is the 1.6usd support line from which it can bounce up.
